Commercialization Alternatives In The New Medtech World
In the current medtech environment, much attention is paid to evolving strategies to deal with the new challenges private companies are facing in areas like financing and regulatory, and a company’s sales strategy can be left for last or thought to be a topic for an acquirer. The authors describe the challenges that are emerging in the current medtech climate that make an early choice of a sales approach – from a variety of options – an important part of a company’s overall strategy. Not only can the choice of a viable commercialization strategy help drive revenue, it also can increase a company’s valuation at exit.
You may also be interested in...
Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.
Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.